Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/38664
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCassinello, J
dc.contributor.authorArranz, J Á
dc.contributor.authorPiulats, J M
dc.contributor.authorSánchez, A
dc.contributor.authorPérez-Valderrama, B
dc.contributor.authorMellado, B
dc.contributor.authorCliment, M Á
dc.contributor.authorOlmos, D
dc.contributor.authorCarles, J
dc.contributor.authorLázaro, M
dc.date.accessioned2019-06-28T18:54:21Z-
dc.date.available2019-06-28T18:54:21Z-
dc.date.issued2018-01
dc.identifier.citationClin Transl Oncol.2018 Jan;(20)1:57-68
dc.identifier.urihttps://hdl.handle.net/20.500.12530/38664-
dc.description.abstractAndrogen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectAbiraterone
dc.subjectAndrogen deprivation treatment
dc.subjectCabazitaxel
dc.subjectCastration-resistant prostate cancer
dc.subjectDocetaxel
dc.subjectEnzalutamide
dc.subjectHormone-sensitive advanced prostate cancer
dc.subjectRadium 223
dc.subject.meshAntineoplastic Agents
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshProstatic Neoplasms
dc.titleSEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
dc.typeArtículo
dc.identifier.pubmedID29134562
dc.format.volume20
dc.format.page57-68
dc.identifier.e-issn1699-3055
dc.identifier.journalClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.identifier.doi10.1007/s12094-017-1783-2
dc.format.number1
dc.identifier.pmcPMC5785604
dc.pubmedtypeJournal Article
dc.pubmedtypePractice Guideline
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC5785604.pdf439.91 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.